All pharma companies in the first round of Medicare price negotiations agree to participate
All companies with drugs on CMS’ list for the first round of Medicare price negotiations under the Inflation Reduction Act have agreed to participate as of this morning, the deadline by which companies had to submit new drug data to CMS.
Johnson & Johnson, Amgen and Novartis have all signed negotiation agreements ahead of the Oct. 1 deadline, they told Endpoints News on Monday. Novo Nordisk also agreed to participate, Endpoints learned on Sunday. Merck, Boehringer Ingelheim, Bristol Myers Squibb and AstraZeneca previously announced their intentions to agree to the negotiations. Companies that do not comply would face a heavy tax or risk losing out on Medicare and Medicaid coverage altogether.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.